• Publications
  • Influence
Suramin analogues as subtype-selective G protein inhibitors.
TLDR
The results show that it is possible to design G protein inhibitors that target the effector binding site on the alpha subunits, and selected suramin is selective for recombinant Gsalpha-s and recombinant Go alpha.
NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors
TLDR
The subnanomolar potency at rP2X1 receptors and the rank order of potency, P 2X1 >> P2X3 > P 2Y1 > P2Y2 > ecto-nucleotidases, make NF449 unique among the P2 receptor antagonists reported to date.
Gsalpha-selective G protein antagonists.
TLDR
Two compounds, NF503 and NF449, fulfill essential criteria for Gsalpha-selective antagonists and demonstrate the feasibility of subtype- selective G protein inhibition.
Structure-activity relationships of suramin and pyridoxal-5'-phosphate derivatives as P2 receptor antagonists.
TLDR
This work moves closer to the ideal goal of classifying the recombinant and native P2 receptor subtypes on the basis of antagonist profiles, and focuses on structure-activity relationships of PPADS and suramin analogues.
Suramin and suramin analogs activate skeletal muscle ryanodine receptor via a calmodulin binding site.
TLDR
It is concluded that NF307 and suramin interact directly with a calmodulin binding domain of the ryanodine receptor, a potent calcium-sensitizing effect that may represent a lead compound in the search of synthetic ryanode receptor ligands.
...
...